1. Biomarkers (e.g. alkaline phosphatase levels) | |
2. Clinical manifestations (e.g. lower limb deformities, linear growth) | |
3. Imaging (e.g. pseudofracture healing, deformity analysis) | |
4. Patient-reported outcomes (e.g. pain) | |
These markers depend on the age of the person living with XLH and status of their disease [2, 7, 21] |